Cargando…

Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy

Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jianshe, Ho, Gilbert, Masliah, Eliezer, Hashimoto, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Commentaries and Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928476/ https://www.ncbi.nlm.nih.gov/pubmed/36785484 http://dx.doi.org/10.1080/19336896.2023.2172912

Ejemplares similares

Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability
por: Hashimoto, Makoto, et al.
Publicado: (2020)

Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
por: Ho, Gilbert, et al.
Publicado: (2022)

Evolvability of Amyloidogenic Proteins in Human Brain
por: Hashimoto, Makoto, et al.
Publicado: (2018)

Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?
por: Waragai, Masaaki, et al.
Publicado: (2020)

Connecting Alzheimer’s Disease With Diabetes Mellitus Through Amyloidogenic Evolvability
por: Ho, Gilbert, et al.
Publicado: (2020)

Therapeutic Potential of α-Synuclein Evolvability for Autosomal Recessive Parkinson's Disease
por: Wei, Jianshe, et al.
Publicado: (2021)

Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease
por: Wei, Jianshe, et al.
Publicado: (2021)

Cognitive impairment in multiple system atrophy: Changing concepts
por: Abrahão, Agessandro, et al.
Publicado: (2011)

Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease
por: Waragai, Masaaki, et al.
Publicado: (2020)

Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability
por: Hashimoto, Makoto, et al.
Publicado: (2018)

Transgenerational Interaction of Alzheimer’s Disease with Schizophrenia through Amyloid Evolvability
por: Takamatsu, Yoshiki, et al.
Publicado: (2019)

Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease
por: Hashimoto, Makoto, et al.
Publicado: (2019)

Infectious causes of multiple sclerosis
por: Gilden, Donald H
Publicado: (2005)

Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates
por: Hashimoto, Makoto, et al.
Publicado: (2018)

Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment
por: Cortelli, Pietro, et al.
Publicado: (2019)

Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-Synuclein
por: Fujita, Masayo, et al.
Publicado: (2020)

Phage therapy dosing: The problem(s) with multiplicity of infection (MOI)
por: Abedon, Stephen T.
Publicado: (2016)

Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
por: Krismer, Florian, et al.
Publicado: (2014)

Recommendations for observational studies of comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Visibility and representation of women in multiple sclerosis research
por: Thomson, Alison, et al.
Publicado: (2019)

Multiple system atrophy with hippocampal pathology
por: Jellinger, Kurt A.
Publicado: (2022)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

Cognition in multiple sclerosis: State of the field and priorities for the future
por: Sumowski, James F., et al.
Publicado: (2018)

Improving quality, affordability, and equity of multiple sclerosis care
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Motor and Nonmotor Symptoms of Parkinson's Disease: Antagonistic Pleiotropy Phenomena Derived from α-Synuclein Evolvability?
por: Takamatsu, Yoshiki, et al.
Publicado: (2018)

Nonconventional MRI biomarkers for in vivo monitoring of pathogenesis in multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2014)

Can We Treat Secondary Progressive Multiple Sclerosis Now?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

The 2013 clinical course descriptors for multiple sclerosis: A clarification
por: Lublin, Fred D., et al.
Publicado: (2020)

Chronic cerebrospinal venous insufficiency in Multiple Sclerosis: A note for caution
por: Bhatia, Rohit, et al.
Publicado: (2012)

The topographical model of multiple sclerosis: A dynamic visualization of disease course
por: Krieger, Stephen C., et al.
Publicado: (2016)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

An argument for broad use of high efficacy treatments in early multiple sclerosis
por: Stankiewicz, James M., et al.
Publicado: (2019)

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021)

Oligodendroglial α‐synucleinopathy‐driven neuroinflammation in multiple system atrophy
por: Hoffmann, Alana, et al.
Publicado: (2019)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Music-based therapy in rehabilitation of people with multiple sclerosis: a systematic review of clinical trials
por: Lopes, Josiane, et al.
Publicado: (2021)

Clinical studies involving probiotics: When FDA’s investigational new drug rubric applies—and when it may not
por: Degnan, Fred H.
Publicado: (2012)

Evaluation of Multiple System Atrophy Subtypes with FDG-PET
por: Jellinger, Kurt
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_loqhu47epcthku99eb69e54ll0